CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
- Agreement creates strong synergies between CureVac’s unique end-to-end mRNA capabilities and MD Anderson’s translational and clinical research expertise
- Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
- MD Anderson responsible for leading initial Phase 1/2 studies; CureVac retains worldwide exclusive rights to late-stage development, commercialization, or partnering of cancer vaccine candidates
CureVac N.V. (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.